12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cardiokine, Cornerstone Therapeutics deal

Cornerstone acquired cardiovascular disease company Cardiokine. Cardiokine shareholders will receive $27.3 million in cash up front and will be eligible for up to $137 million in sales milestones for hyponatremia compound lixivaptan, plus 8% or 12% royalties, depending on labeling....

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >